Search
GWAS ID | Year | Trait | Consortium | Sample size | Number of SNPs |
---|---|---|---|---|---|
ebi-a-GCST90085790 | 2022 | VEGFR 3 plasma levels | NA | 400 | 5,188,525 |
ebi-a-GCST90085791 | 2022 | YKL 40 plasma levels | NA | 400 | 5,188,525 |
ebi-a-GCST90093091 | 2021 | DHEAS levels | NA | 398 | 5,459,647 |
ebi-a-GCST90093342 | 2020 | Neutralising antibody response to interferon beta therapy in multiple sclerosis in patients positive for neutralising antibodies (antibody titre; IFN<U+03B2>-1a subcutaneous) | NA | 391 | 7,852,590 |
ebi-a-GCST90013831 | 2021 | Cisplatin-induced hearing loss in childhood cancer | NA | 390 | 7,754,919 |
Data overview
The GWAS summary datasets are currently organised into the following 18 batches: